Skip Navigation LinksHome > January 2012 - Volume 30 - Issue 1 > Use of aliskiren in a ‘real-life’ model of hypertension mana...
Journal of Hypertension:
doi: 10.1097/HJH.0b013e32834e1c66
Original papers: Therapeutics aspects

Use of aliskiren in a ‘real-life’ model of hypertension management: analysis of national Web-based drug-monitoring system in Italy

Volpe, Massimoa,b; Tocci, Giulianoa,b; Bianchini, Francescac; De Rosa, Marisad; Fedozzi, Elisabettad; Covezzoli, Annad; Maggioni, Aldo P.c; AIFA Drug Monitoring Program: Aliskiren Registry

Supplemental Author Material
Erratum

Erratum

The authors have noted the following required corrections to their article [1].

One page 197, 2nd column, 3rd paragraph, the frequency of prescription for CCBs was 54.9% and not 48.1%.

On page 198, 2nd paragraph of the section “Blood pressure levels during follow-up period” the change in prevalence of hypertensive outpatients achieving the recommended SBP targets patients from 1-month clinical data was “(from 11.9 to 30.0%; P < 0.001)” and not “(from 11.5 to 29.9%; P < 0.001)”.

On page 198, 4th line of the 2nd column the percentage value should have been 26.5% and not -(minus) 26.5%.

On page 198, in the last sentence of the section “Safety and tolerability” the percentage of patients that discontinued the drug treatment at months 1 and 6 of follow-up was 1.7 and 1.3%, respectively, and not 1.4 and 0.9%, respectively. The data was also from the supplementary data in Figure S3 and not Table S4 as indicated.

Journal of Hypertension. 30(4):836, April 2012.

Collapse Box

Abstract

Introduction: In Italy, prescriptions of the direct renin inhibitor aliskiren (aliskiren) to high-risk hypertensive patients must be electronically filled by specialized physicians only when at least two antihypertensive drug classes (independently of the dosages), fails to normalize blood pressure (BP) levels.

Aim: To analyze the effects of the addition of aliskiren 150–300 mg daily to antihypertensive therapy in a population of high cardiovascular risk hypertensive patients with uncontrolled BP levels.

Methods: Clinical data were derived from patients included in the national Web-based drug-monitoring system. Follow-up visits were required for measuring BP levels, and collecting data on drug safety and tolerability.

Results: Between March 2009 and February 2010, aliskiren was prescribed by 6464 specialized physicians to 11 511 treated, uncontrolled hypertensive patients (47.6% women, aged 68.0 ± 11.1 years, BMI 28.4 ± 4.9 kg/m2) with organ damage or comorbidities. During 6-month observation, only a few drug-related side-effects were reported (n = 33). At the entry and 1-month follow-up visits (n = 8197; 70.6%), BP levels were 158.9 ± 16.8 and 142.1 ± 15.2 mmHg for SBP and 90.8 ± 9.6 and 83.1 ± 8.5 mmHg for DBP, respectively. At 6-month (n = 4907; 42.3%), SBP and DBP levels were 137.9 ± 13.9 and 81.3 ± 8.0 mmHg, respectively. A consistent reduction in the use of all classes of concomitant antihypertensive drugs was recorded.

Conclusion: Although data derived from national registries need to be interpreted with caution, the Italian Web-based drug-monitoring system provided information on ‘real-life’ use of aliskiren in hypertension. In this uncontrolled, high-risk treated hypertensive population, SBP and DBP levels recorded during treatment with aliskiren were consistently lower than those recorded at entry visits in a context of a very low rate of reported side-effects.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.